Podcasts about AAV

Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease. Alltrna is testing a different idea: that the real target isn't the gene, but the process of translation itself, where genetic instructions become protein. The company's lead approach focuses on nonsense mutations, a shared error responsible for roughly a tenth of all genetic disease diagnoses, and asks whether a single engineered molecule could address it across many conditions at once.My guest today is Dr. Nerissa Kreher, Chief Medical Officer of Alltrna. Nerissa brings two decades of rare disease drug development experience, including CMO roles at Entrada Therapeutics, Tiburio Therapeutics, and AVROBIO, to the task of turning that platform thesis into an actual clinical program. We'll talk translation, trial design, and what it takes to bring the first engineered tRNA therapy into the clinic.02:45 Meet Nerissa Kreher and Alltrna's tRNA platform07:29 Gene-by-gene versus mutation-by-mutation drug development12:08 What nonsense mutations are and why they matter15:55 Phase 1 trial approval in Australia19:49 What basket trials are and FDA receptiveness27:27 Where Alltrna could be in five yearsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Beyond Biotech - Episode 66: treating rare diseases with tRNAWill tRNA therapy be the next big thing in genetic disease treatment?Pharma giants pull back on AAV research: what's next for the gene therapy space?

Two young NHL stars just cashed in.Minten signs a 7-year, $7.2 million AAV deal, while Buium lands an 8-year, $9.38 million AAV contract. With the window for 8-year extensions closing, who could be the next NHL player to get a long-term deal? Denton Mateychuk is one name to watch.Plus, Brock Seguin joins Daily Faceoff Live for a 2026-27 fantasy hockey preview, including the latest fantasy tools, the team that has stood out during his previews, how to approach the Washington Capitals, the elite fantasy goalie tier, late-round targets and how to handle disgruntled players like Connor Hellebuyck and Dylan Larkin.Plus, your #AskDFO questions and Garbage Time.

Vancouver Canucks General Manager Ryan Johnson announced today that the Canucks have agreed to terms with defenceman Zeev Buium on an eight-year contract extension with a $9.38 million AAV.I talk about the massive extension and how this could turn out to be an amazing deal for the Canucks.

The NHL's salary landscape has officially changed.Jason Gregor and Jeff Marek break down Cale Makar's massive $20.4 million AAV extension with the Colorado Avalanche, the new benchmark it creates for NHL superstars, and what the deal could mean for the next wave of contracts, including Quinn Hughes and Adam Fantilli.The guys debate whether players should be expected to take less money to help their teams win, how rapidly the NHL salary cap is rising, and what a potential $150 million salary cap could mean for superstar contracts in the future.Then, the conversation turns to two of the NHL's biggest trade situations: Connor Hellebuyck and Dylan Larkin. Hellebuyck has publicly requested a trade from Winnipeg, but with no deal completed yet, what is holding things up? The guys discuss his market, Winnipeg's options and whether Hellebuyck could still be with the Jets when training camp opens.They also break down the complicated situation surrounding Dylan Larkin and the Detroit Red Wings, including the team's search for a new general manager, Larkin's limited trade destinations, his captaincy and whether Detroit should wait for its new GM before making a franchise-altering decision.Plus, Jason and Jeff debate whether NHL rivalries are being underutilized, why the league should schedule more rivalry games and how creating more meaningful matchups could help increase fan engagement.The episode also features Buy or Sell, including Quinn Hughes' next contract and whether the Washington Capitals have done enough to become legitimate Stanley Cup contenders, plus Brady Tkachuk's expected impact with the Florida Panthers.

This Detroit Red Wings podcast welcomes top-ranked Red Wings prospect Trey Augustine for his first-ever interview on the show ahead of training camp! Hockeytown news & analysis covers the GM search candidates, Simon Edvinsson's unsigned contract, & Cale Makar's record-setting deal in Colorado. (00:00) - Intro & Episode Preview (05:40) - Trey Augustine Interview The goalie prospect on signing his entry-level contract, his thoughts on the Sebastian Cossa trade, his Michigan State years, back-to-back World Juniors golds, his ATO with the Grand Rapids Griffins, growing up watching Pavel Datsyuk at the Joe, and why he's going into camp on a mission. (35:30) - Red Wings Notes GM Search Update Jeff Kealty, Brett Peterson, and Scott White among the reported external interviews: what each candidate brings and why the lack of retreads is encouraging. Also notes on Eddie Genborg and the looming Mason/Lucas Raymond nightmare continuing on national broadcasts. (51:30) - Makar's Record Contract, Quinn Hughes' Contract & Hellebuyck Trade Request The richest deal in NHL history at $20.4 million AAV and what a blank-check superstar market means going forward. Minnesota's cap crunch just got scarier, and Connor Hellebuyck goes public in Winnipeg, plus how both situations ripple back to Detroit's Dylan Larkin trade rumors. (1:04:55) - Overtime: Patron Questions When to hit the panic button on the Edvinsson contract, deadline returns for expiring deals, and which Canadian city would get the next expansion team (or rather why almost none will anytime soon). --- WWP Night at the LCA dates announced! Get your tickets for the Nov. 21st game here:  wingedwheelpodcast.com/redwings Refresh your wardrobe with Quince - go to Quince.com/WINGEDWHEEL for free shipping and 365-day returns! This episode is brought to you by Hims. Visit hims.com/wingedwheel for your personalized hair loss treatment options. Support the show: Patreon.com/WingedWheelPodcast Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more!

HOUR 3 - All hail Cale! Colorado Avalanche defenceman Cale Makar has signed the biggest deal in NHL history. His 8 year extension with the Avs comes with a $20.4 million AAV. Also, yesterday we found out that Winnipeg Jets star goaltender, Connor Hellebuyck, has requested a trade out of Winnipeg. With a no-trade clause in his contract, that limits the teams Winnipeg can try to make a trade with. Will Winnipeg be able to get assets back to replace Hellebuyck or is this the beginning of some dark times for the Jets? The Green Zone

In hour 3 of The Drive, Phil and Aniello preview Cale Makar's looming contract extension. How soon are we expecting to see news of his extension? Will Makar take the most amount of money possible, or will he settle for an AAV in the teens? Could Makar sign a shorter-term deal so he can leave his option open to sign a bigger deal in 4 years or leave the Avalanche in free agency if the team isn't competitive anymore? Are we seeing teams change their approach on early downs against the Broncos? How can the Broncos defense still put offenses in uncomfortable situations where they pin their ears back and rush the passer? We react to Ben Solak's rankings of the most watchable teams in the NFL. Are the Broncos underrated in the excitement that comes with watching a team that played in so many close games last year? 

Hour 1 of The Drive kicks off with Aniello and Phil cross-talking with Dover and Cecil. The guys discuss the Broncos' running back room. Phil makes the case for the Broncos to keep 4 running backs on the active roster as an insurance plan for JK Dobbins. Phil and Aniello preview Cale Makar's looming contract extension. How soon are we expecting to see news of his extension? Will Makar take the most amount of money possible, or will he settle for an AAV in the teens? We react to Sean Payton getting into it on Twitter and calling out a media member for his criticism of Bo Nix and not throwing the ball downfield. Is there a false narrative that Bo Nix doesn't throw the ball downfield or throw it in the middle of the field? We react to Ben Solak's rankings of the most watchable teams in the NFL. Are the Broncos underrated in the excitement that comes with watching a team that played in so many close games last year? 

Gene therapy only works if the cargo reaches the right cells intact. Adeno-associated viruses (AAV) and lipid nanoparticles have carried the field this far, but both share a constraint: the particle is taken up into an endosome, and the payload has to escape that compartment before it is degraded. Endosomal escape is where a large share of the dose is lost, and it is why delivery, not the genetic construct, is usually the thing that limits the therapy. Lipid nanoparticles carry a second constraint, since they tend to accumulate in the liver, which narrows the diseases they can reach. What if the particle never entered that way at all?Jitendra Kumar, Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, works on a platform that fuses directly with the cell membrane and releases its cargo straight into the cytosol. He came to nanoparticle design the long way, through fifteen years of structural biology on the prion protein in Frankfurt and Edmonton, which is why he thinks about particle size, packaging and diffusion the way he does.Key topics discussed:Jitendra's career background in structural biology and journey to Entos Pharmaceuticals (03:18)The scientific motivation and challenges of working with prion proteins and breaking down complex diseases (04:55)Genetic medicine approaches: gain-of-function vs. loss-of-function, and the role of siRNA, ASOs, and gene delivery (06:27)The FAST protein platform: origins, function, and advantages for drug delivery (07:56)Manufacturing differences compared to LNPs, including the introduction of recombinant membrane protein production and related CMC complexity (09:55)Scale-up and production challenges for membrane proteins, and strategies for clinical supply (11:21)Clinical development progress: Phase 1/2 studies with the platform, especially for COVID vaccine delivery (12:23)Focus areas for the technology, including selective lung delivery and leptin therapy for lipodystrophy (13:12)Lessons for small biotech companies in phase 1/2 manufacturing strategy, technology transfer, and the value of an experienced network (14:31)Balancing process robustness with speed in new biotech ventures (16:02)The importance of identifying “pause steps” and must-have vs. nice-to-have features in early manufacturing processes (17:15)Smart insight: Jitendra's takeaway for startups: for early phases, find a partner who genuinely understands your tech and can move at your pace rather than defaulting to a big CDMO, treat your network as infrastructure, and build the ability to run production in-house. The one thing that's never up for negotiation is process robustness. The real question isn't robustness vs. speed, but how many checkpoints and safe pause points you build in so you can have both.If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper:Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed YoussefEpisodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark MelvilleConnect with Jitendra Kumar:LinkedIn: www.linkedin.com/in/jkumar2Email: jitendra.kumar@entospharma.comWebsite: www.entospharma.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it hereSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into recent strides made in scientific research, regulatory landscapes, and market dynamics that are shaping the future of healthcare. Starting with a significant breakthrough in cancer treatment, Merck & Co. and Moderna have reported promising results from their Phase 3 melanoma trial. Their investigational mRNA-based vaccine, intismeran autogene, when paired with Keytruda, has shown a substantial reduction in melanoma recurrence risk. This combination exemplifies the growing role of mRNA technology in oncology, moving beyond its initial success with infectious diseases. The synergy between mRNA platforms and immune checkpoint inhibitors like Keytruda underscores a pivotal shift in cancer therapeutics, potentially transforming treatment paradigms with more targeted and personalized approaches. On the regulatory front, Heidi Overton's nomination as the new FDA Commissioner marks a critical juncture for the agency. Her leadership could bring fresh perspectives to drug approval processes at a time when swift regulatory actions are essential to bring innovative therapies to market. This shift in FDA leadership is expected to influence the speed and efficiency with which new treatments reach patients, highlighting the agency's evolving role in balancing innovation with safety. In Singapore, GSK's Blenrep has received approval for use in combination therapies targeting relapsed or refractory multiple myeloma. This antibody-drug conjugate specifically targets the BCMA protein on myeloma cells, offering new hope for patients who have exhausted conventional treatment options. The approval exemplifies ongoing advancements in targeted therapies aimed at improving outcomes for complex cancers. The industry is also witnessing strategic collaborations that could reshape clinical trial access and efficiency. Merck & Co.'s partnership with Sarah Cannon Research Institute aims to enhance community-based oncology trials through the Accelero model, democratizing access to cutting-edge cancer therapies. By bringing trials closer to patients, this initiative could accelerate data collection and recruitment efforts, ultimately benefiting patient outcomes. In manufacturing advancements, Genprex's collaboration with an undisclosed CDMO to scale up its AAV-based diabetes gene therapy production is noteworthy. This partnership is crucial for advancing gene therapy solutions targeting chronic diseases like diabetes, offering potential long-term treatment efficacy through innovative therapeutic platforms. Financially, CSL has experienced a resurgence following increased demand for immunoglobulin products, resulting in stronger-than-expected revenue figures. This rebound highlights the resilience of plasma-derived therapies and signals growing market demand amid fluctuating global health challenges. PitchBook's prediction of a resurgence in biotech venture capital funding further underscores the sector's dynamic nature. This anticipated investment influx is likely to drive demand for CDMOs specializing in cell and gene therapy manufacturing over the next few quarters, reinforcing the industry's growth trajectory. In clinical trial news, Enveda's ENV-308 has successfully cleared its Phase 1 safety trial for obesity management by targeting appetite suppression pathways involving GLP-1 and lac-phe mechanisms. As it progresses to Phase 2 trials, this novel approach represents a significant advancement in addressing metabolic disorders through innovative therapeutic avenues. Conversely, regulatory setbacks continue to challenge manufacturers. Aurobindo's Eugia unit received an FDA warning letter over sterile manufacturing violations, emphasizing the importance of maintaining stringent quality standards within pharmaceutical production processes. Overall, these developments highlight a dynamic industry poised at the intersection of scientific innovation and regulatory evolution. The implications for patient care are profound as new therapies emerge with enhanced efficacy and safety profiles across various disease spectrums. Continuous collaboration between industry players and regulatory bodies remains vital to sustaining momentum and ensuring groundbreaking treatments efficiently reach those in need. That's it for today's briefing on Pharma Daily. Stay tuned as we continue to track these developments and more within this ever-evolving landscape of pharmaceutical and biotech industries. Stay informed and stay ahead!Support the show

Why is gene therapy still so difficult to manufacture at scale after decades of progress?Phillip Ramsey, Chief Technical Officer at Sangamo Therapeutics, joins BioTalk Unzipped for a candid conversation about one of the central challenges facing advanced therapies: turning extraordinary science into reproducible, scalable medicines.Thank You to Our SponsorsLeucentra - https://leucentra.com/Inspired by Science. Empowered by IT. Leucentra provides specialized IT consulting and services for life sciences and healthcare, helping organizations use technology more effectively to support innovation.TruTechnologies - https://trutechnologies.ai/Clinical Trial Execution, Live. TruTechnologies provides live clinical trial execution technology that gives sponsors greater visibility into protocol activities, samples, and study data as they happen.About This EpisodeRecorded onsite at the AAPS National Biotechnology Conference in Boston, Phillip explains why gene therapy manufacturing has not yet reached the maturity of monoclonal antibody production.As technologies have evolved across retroviral vectors, lentiviral vectors, adenovirus, AAV, lipid nanoparticles, and other advanced modalities, development teams have repeatedly been required to rethink fundamental manufacturing and analytical questions.Phillip discusses why analytics are critical, why experience across multiple manufacturing lots and products matters, and why there simply is no shortcut to developing the scientific knowledge necessary to manufacture advanced therapies reliably.He also reflects on the uncertainty of biotechnology.Early in his career, Phillip was walking down a hallway when his CFO asked if he had cashed his paycheck.When he said no, she told him not to.It's a remarkable story that captures something rarely discussed about biotechnology: behind transformative science are people willing to operate through considerable uncertainty while trying to build something that has never existed before.Gregory and Phillip Discuss• Viral vector manufacturing and scale-up• Why analytics are essential to gene therapy development• AAV manufacturing challenges• Lentiviral vectors and other evolving delivery technologies• Lipid nanoparticles and changes in advanced therapy manufacturing• Why gene therapy cannot simply adopt the established monoclonal antibody manufacturing playbook• Building process knowledge across lots and products• Career resilience in biotechnology• Progress across AAV, CAR-T, and other advanced therapies• Gene therapy affordability• The importance of therapeutic durability• Outcomes-based payment models for advanced therapiesPhillip's message for scientists and industry leaders is straightforward: don't assume the manufacturing problem has already been solved simply because a technology has existed for decades.The field is still evolving, and some knowledge cannot be shortcut.About Phillip RamseyPhillip Ramsey is Chief Technical Officer at Sangamo Therapeutics and brings more than 35 years of experience across biotechnology and pharmaceutical manufacturing, technical development, operations, quality, and advanced therapies.Connect with Phillip Ramsey:https://www.linkedin.com/in/phillip-ramsey-a2074711/Sangamo Therapeutics:https://www.sangamo.com/Connect With BioTalk UnzippedGregory Austin on LinkedIn:https://www.linkedin.com/in/gregoryaustin1/Dr. Chad Briscoe on LinkedIn:https://www.linkedin.com/in/chadbriscoe/BioTalk Unzipped:https://www.biotalkunzipped.com/BioTalk Unzipped unzips, unlocks, and uncovers the stories behind medical progress through conversations with scientists, executives, entrepreneurs, and innovators advancing biotechnology, pharmaceuticals, and medical technology.Recorded onsite at the AAPS National Biotechnology Conference in Boston.Special thanks to AAPS and Rebecca Stauffer for supporting the BioTalk Unzipped interview series.

Tony is back with Jeff/Waleed/Evan to discuss AAV and price setting for auction redraft leagues! Hosted on Acast. See acast.com/privacy for more information.

Jahmyr Gibbs signed a three-year extension with the Detroit Lions that makes him the NFL's highest paid running back by average annual value. As Jeff Risdon reported live, the deal can reach $75,750,000 with $51,500,000 guaranteed, ending any contract chatter and securing Detroit's most explosive skill player. What exactly did the Detroit Lions pay Jahmyr Gibbs? The Lions committed to three years, up to $75,750,000 with $51,500,000 guaranteed. Jeff Risdon also noted the structure as three years 67.5 that includes 51.5 guaranteed and can reach 75.75. That places Detroit Lions running back Jahmyr Gibbs at the top of the position on a per-year basis. How did the market set up this number? Indianapolis Colts running back Jonathan Taylor signed this morning for two years and $44,000,000, and Atlanta Falcons running back Bijan Robinson was referenced at up to $75,000,000. Detroit waited for others to set the market, then finalized Gibbs at the top without acrimony or (much) drama. Why was there never real tension around this deal? There was no standoff and no acrimony. Detroit Lions head coach Dan Campbell showed no stress at camp's open, and Gibbs missing early practices did not change the tone. As Jeff Risdon explained, the Lions expected a deal and let the market finalize first, then closed it quickly. This was not a drawn-out negotiation. The team and player remained aligned, Detroit moved decisively once comparable numbers were public, and they eliminated a distraction before it could dominate press conferences. Quarterback Jared Goff will not field contract questions about his running back anymore. How does this fit the Lions' roster-building strategy? Detroit pays its core and keeps windows open with smart term. The Lions have already invested in right tackle Penei Sewell, defensive tackle Alim McNeill, edge rusher Aidan Hutchinson, linebacker Jack Campbell, safety Kirby Joseph, and tight end Sam LaPorta stands out as a logical next extension candidate. As Jeff Risdon noted, shorter deals deliver more control, more bonuses, and better player leverage, a trend popularized by Kirk Cousins. Gibbs is 24, and his run plus receiving profile matches the modern value proposition. Detroit Lions running back Jabari Small has flashed in camp, but Gibbs does things that cannot be coached or diagrammed. That is why Detroit prioritized him and why his number sits atop a quickly moving market. What does this mean for 2026 expectations? Detroit must win at the highest level. Jeff Risdon said this is Detroit's best chance to win the NFC, with the Rams, Seahawks, Chicago, Green Bay, and San Francisco providing real competition. Health and one poor offensive coordinator hire last year were the recent obstacles, not talent. Gibbs changes outcomes. As Risdon put it, he can turn any play into a big play from anywhere on the field. The Detroit Lions Podcast take is straightforward, and the contract confirms it: Detroit secured a championship-caliber core, and the highest-paid running back in the NFL by AAV is a central pillar of that push. #detroitlions #lions #detroitlionspodcast #jahmyrgibbs #three-yearextension #highest-paidrunningback #51.5millionguaranteed #75.75million #averageannualvaluerecord #jonathantaylorcontract #bijanrobinsonreference #dancampbell #jaredgoff Learn more about your ad choices. Visit megaphone.fm/adchoices

Your (mourning Skubal) Detroit Red Wings podcast tackles the Alex DeBrincat contract situation as the Dylan Larkin fallout continues. Hockeytown news & analysis breaks down the GM search timeline, the ideal front office structure, and the contracts waiting on the desk of whoever replaces Steve Yzerman. (00:00) - Intro A rough stretch for Detroit sports as Tigers fans mourn the loss of Tarik Skubal. (04:45) - DeBrincat Contract Situation Alex DeBrincat has one year left on his deal and the Red Wings have almost zero leverage. What a fair extension looks like in an exploding goal-scorer market, whether a mega-deal is stomachable, and if the captaincy should be on the table. (24:10) - GM Search Timeline Why the hire needs to happen before September, with Simon Edvinsson's contract sitting unsigned and monumental decisions stacking up for the new regime. (34:10) - Front Office Structure President of Hockey Ops vs. a lone-voice GM: why the roster shakeup era demands collaboration, filling out competencies, and hiring an elite recruiter over a one-man show. (45:50) - Around the NHL Macklin Celebrini's five-year, $18.8 million AAV deal in San Jose and what shorter superstar contracts mean for the cap era. Plus, why Quinn Hughes still isn't extended in Minnesota and how it circles back to Detroit. (56:25) - Overtime Patron questions on Moritz Seider's Norris chances, 20-goal targets for the young forwards, and the risk of a soft reset built around Lucas Raymond. ~~~~~ Refresh your wardrobe with Quince - go to Quince.com/WINGEDWHEEL for free shipping and 365-day returns! Go to TempoMeals.com/WINGEDWHEEL  for 60% off your first box! #ad Support the show: Patreon.com/WingedWheelPodcast Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more!

We got to interview Alex Ovechkin at Fanatics Fest and it was the best day of all time!!! Macklin Celebrini signed for 18.8 million AAV and is now the highest paid player in NHL history. Quinn Hughes could make a decision this week. Spider Man comes out tomorrow and the boys are fired up. Fraud Watch and Top Hits are going to get Sean in trouble again… And a Blind Ranking that's nearly perfect. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode recorded live at the ASGCT 2026 Annual Meeting in Boston, host Eirini Vamva, PhD interviews Anna Maurer, PhD of the University of Michigan. Dr. Maurer shares her story of growing up in Michigan and how her path led her to Harvard Medical School. She discusses her work in AAV and gives advice to individuals looking to enter the field of cell and gene therapy. Music: 'Dreamer' by Steven O'Brien – Released under CC-BY 4.0. https://www.steven-obrien.net/Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Dustin Nielson and YouTube Trev are live on location at Boston Pizza for a Wing Wednesday edition of The Oil Stream! Tune in as we digest a massive contract drop that sent shockwaves across the entire NHL before diving into some rapid-fire Oilers talk!   On Today's Show: BREAKING NEWS — Macklin Celebrini Gets THE BAG! Holy crap! News broke earlier this morning that San Jose Sharks superstar Macklin Celebrini has re-signed on a staggering five-year, $94 million extension boasting a record-shattering $18.8 million AAV! Is he worth the biggest cap hit in NHL history? Did he leave any money on the table for future stars? What is his absolute point ceiling in San Jose? The fellas debate the massive deal from all angles. 10 Oilers Questions for YouTube Trev: Once the Celebrini chaos settles, Dusty puts Trev in the hot seat with 10 prepped questions about the Edmonton Oilers heading into the upcoming season. Roster depth, line combinations, and hot takes—Trev gives his unfiltered answers!   The Oil Stream is presented by Boston Pizza!

San Jose and Macklin Celebrini are re-setting the bar with an AAV of 18.8M on a 5 year deal for the start of the 2027-28 season. Jim Toth, Brayden Ewasko, and Kelly Moore toss around the idea of which NHL player will be the FIRST to raise the bar to 20M per season. Learn more about your ad choices. Visit megaphone.fm/adchoices

SHOWTIME! #88, Patrick Kane, is BACK in a Chicago Blackhawks uniform, after agreeing to a two-year, $8 million AAV contract on Thursday morning. Blackhawks Cowboy and Ron Luce discuss the return of an all-time Blackhawk, how the roster shapes up for the season as a result, and so much more. Four Feathers Pod is presented by ⁠⁠⁠⁠⁠OnTapSportsNet.com⁠⁠⁠⁠⁠, your go-to source for Blackhawks news⁠⁠⁠⁠⁠, analysis, and updates.Please support the show: Purchase your ⁠⁠Chicago Blackhawks gear⁠⁠ from Fanatics through our link!Follow us on social media: ⁠⁠⁠⁠⁠@FourFeathersPod | ⁠⁠⁠⁠⁠@OnTapSportsNet⁠⁠⁠⁠⁠Panelists: ⁠⁠⁠⁠⁠@TonyOnTap⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠@LuceOnTap | @BHawkCowboy

The Philadelphia Flyers have signed defenseman Jamie Drysdale to a four-year, $26 million contract extension, the team announced on Friday afternoon. That's an average annual value (AAV) of $6.5 M for the 24-year-old. Steve Jacot and Jacob Russell react to the news and how it affects the Flyers' long-term plans for the team. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Philadelphia Flyers have signed forward Trevor Zegras to a four-year, $36.5 million contract extension, the team announced on Wednesday night. That's an average annual value (AAV) of $9.125 M for the 25-year-old. Ryan Gilbert and Steve Jacot react to the news and what's next for the Flyers. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

If I had to guess, I would say the offseason moves are about 95% of the way there with Braden Schneider officially minting his new contract. We spend a decent amount of the show discussing the deal and how it changes thing for both player and team. I don't think 5.6m AAV is too far off, but I think most people expected to see longer term. Does the one year bridge deal provide an opportunity to see what you have in the former first round pick, or does the short contract show a more telling window into Schneider's future with the Rangers?Today's episode is sponsored by BetterHelp - use the link below to save on your first subscription!BetterHelp:https://betterhelp.com/broadwayblockInstagram:https://www.instagram.com/broadway_blockTikTok:https://www.tiktok.com/@broadway_blockYouTube:https://www.youtube.com/channel/UC-4OSzH5NKz4EmhVCk0yaZgTwitter:https://twitter.com/Broadway_BlockApple Podcasts:https://podcasts.apple.com/us/podcast/broadway-block/id1646160199Spotify:https://open.spotify.com/show/3KqBFrqn7maexzAnVeqCUH

YouTube Trev and Reid Wilkins anchor the desk today to tear into a massive weekend of Edmonton Oilers hockey operations. With roster building reaching its closing stages and young core pieces locking into place, the fellas are looking at the financial chessboard, debating development timelines, and finishing things off with the ultimate, star-studded hockey debate.   On Today's Show: The Colton Dach Valuation: The big weekend news drops right at the top of the hour. The Oilers officially signed restricted free-agent forward Colton Dach to a two-year contract extension carrying a $1.2 million AAV. Did Stan Bowman get the right price for the physical 23-year-old? The guys discuss what realistic expectations look like for Dach's first full season in the bottom six, and whether his heavy frame can provide the consistent grid-work this lineup needs. Playing the Cap Space Matrix: Now that the main roster is essentially set in stone, the Oilers still have a lingering pocket of cash to burn. Trev and Reid debate the next tactical move: Do you jump back into the market to squeeze value out of the remaining unrestricted free agents (UFAs)? Or do you pocket the space, hold the line, and weaponize that cap flexibility ahead of the trade deadline? The Matt Savoie Extension Clock: Coming off an encouraging 18-goal rookie campaign that concluded with a spectacular regular-season finale hat trick, Matt Savoie is officially eligible for his next contract extension. Do the Oilers lock him down immediately to avoid a skyrocketing price tag if he breaks out further this year, or do they wait one more season to get a larger sample size? The All-Time Oilers Ultimate Starting 6 Draft: Because it's the dead of summer, it's time to settle some scores. Trev and Reid go head-to-head in a live fantasy draft to build the greatest all-time, single-game starting lineup in Oilers history. 3 forwards, 2 defensemen, 1 goaltender. The legendary pool is deep, but roster strategy is everything. Who will put together the more dominant unit, and who gets stuck making the toughest cuts?   The Oil Stream is presented by Boston Pizza!

Ben Ennis and Brent Gunning open this episode alongside Gord Stellick, former Maple Leafs GM and friend of the show. They discuss the Leafs' decision to hire former franchise rival Daniel Alfredsson behind the bench, what the move means for the locker room, and the coach's relationship with Mats Sundin and William Nylander. The trio also touch on how the roster has improved since the season ended, and the implications of Leo Carlsson's $18 million AAV offer sheet. Later, former Raptor and current Sportsnet NBA analyst, Alvin Williams (26:18) joins the show to reflect on the Raptors retiring Kyle Lowry's jersey, his legacy in Toronto, the return of Kawhi Leonard, and the possibility of DeMar DeRozan returning to the Raptors after being waived by the Kings. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.

Boomer and Rhett react to one of the biggest offer sheets in NHL history after Leo Carlsson accepted a massive five-year, $90 million deal from the Philadelphia Flyers. With an eye-popping $18 million AAV, the Ducks now face a franchise-altering decision: match the contract and make Carlsson the highest-paid player in the NHL, or walk away and collect four first-round picks in compensation. The guys debate what Anaheim should do, whether the Flyers are making a brilliant gamble or an expensive mistake, and what this blockbuster offer could mean for the future of offer sheets across the league.Video Link: https://youtu.be/mXemUtSuGa8#nhl #nhlshorts #nhlplayoffs #nhlpredictions #nhlhockey #nhlpicks #stanleycup #stanleycupfinal #anaheimducks CHECK OUT OUR STUFF ⬇️BARN BURNER MERCHhttps://nationgear.ca/collections/shirts/FlamesnationBARN BURNER SHORTS https://youtube.com/playlist?list=PLj_bcGtvvo-cW2DHEDZ6dEO5ePDmlhZc9&si=jo8iNGxT4ImhS2Y8

A Note from James:I've been obsessed with anti-aging and longevity science for a long time. I've had many longevity researchers on the podcast, but this episode feels different because something we've been discussing for years has now moved into human trials.David Sinclair first came on the show in 2019, when his book Lifespan was published. He's a professor of genetics at Harvard Medical School, and that first conversation changed how I lived. I started experimenting with intermittent fasting, paid much more attention to sleep, and began researching many of the supplements and lifestyle changes he discussed.But the most important idea David talked about wasn't a supplement. It was the possibility of reversing cellular age using Yamanaka factors—genes that can reset the instructions cells use to function. At the time, nobody knew whether this could be done safely without causing cancer or making cells lose their identities.Now, a therapy based on three of those factors has entered its first human clinical trial. The initial target is age-related damage to the optic nerve, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The trial is designed primarily to evaluate safety, but researchers will also measure visual function.David explains how this technology worked in mice and nonhuman primates, why the eye was chosen as the first organ, and how the same approach might eventually be applied to the liver, lungs, joints, skin, and brain.We also cover the practical questions people always ask him: NMN, NAD, metformin, berberine, testosterone, growth hormone, diet, fasting, sleep, exercise, and what David himself has started—or stopped—taking.This is still experimental science. Nobody yet knows whether the animal results will translate into meaningful benefits for humans. But for the first time, researchers are beginning to test that question directly.About Lifespan: Dr. David Sinclair founded Lifespan to deliver clear, science-backed health insights that help people live longer, more vibrant lives.He's now building the world's largest community dedicated to extending human longevity well beyond today's limits. Join early access at lifespan.com. New episodes of Lifespan with Dr. David Sinclair -- the #1 health and wellness podcast in its first season -- are now available on YouTube, Spotify, Apple Podcasts, and Lifespan.com.Episode Description:For years, longevity researchers have looked for ways to slow the biological processes associated with aging. Dr. David Sinclair and his collaborators are now testing a more ambitious possibility: whether damaged human cells can be restored to a younger, more functional state.The experimental therapy, ER-100, uses controlled expression of three transcription factors—OCT4, SOX2, and KLF4, collectively known as OSK. These are three of the four Yamanaka factors originally used to transform adult cells into pluripotent stem cells.Turning on all four factors can erase too much of a cell's identity and has produced tumors and fatal outcomes in animal experiments. Sinclair's team found that removing one factor, c-MYC, allowed cells to regain younger patterns of gene expression without completely returning to a stem-cell state.In preclinical studies, OSK restored youthful epigenetic patterns, promoted optic-nerve regeneration, and reversed vision loss in mouse models. Life Biosciences, a company Sinclair co-founded, has now moved the technology into a first-in-human Phase 1 trial involving people with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy.David explains how the therapy is delivered directly into the eye and activated using doxycycline, allowing clinicians to control when and for how long the genes are expressed. He also describes the development path that could follow if the treatment proves safe, including therapies targeting the liver and other organs, as well as future medicines that may reproduce similar effects without gene delivery.The conversation then turns to interventions available today. David distinguishes between promising research and claims that have moved ahead of the evidence, discussing NMN, injected NAD, growth hormone, testosterone, taurine, nattokinase, metformin, berberine, and nootropics.Throughout the episode, he emphasizes that no supplement has been shown to reproduce the effects researchers are attempting to achieve through partial epigenetic reprogramming—and that many of the most dramatic claims circulating online remain unsupported.Editorial Note:ER-100 is an investigational therapy. Authorization to begin a clinical trial does not mean the treatment has been proven safe or effective, nor has it been approved for clinical use.The Phase 1 study is primarily evaluating safety and tolerability, with additional measurements of visual function. Results from mice and nonhuman primates do not establish that the therapy will restore vision or reverse biological aging in people.The discussion of supplements, prescription medications, hormones, and lifestyle practices reflects the speakers' personal views and interpretation of the research. It should not be treated as individualized medical advice. Prescription drugs, hormones, supplements, and experimental longevity treatments should be discussed with an appropriately qualified healthcare professional.What You'll Learn:How partial epigenetic reprogramming differs from completely resetting a cell into a stem cell.Why researchers selected three Yamanaka factors—OCT4, SOX2, and KLF4—instead of using all four.What ER-100 is designed to do and why the first human trial focuses on the optic nerve.How doxycycline acts as an external switch controlling when the therapeutic genes are expressed.What Phase 1 researchers will measure and what would need to happen before ER-100 could become an approved treatment.Why the eye provides a useful starting point for testing cellular rejuvenation.What animal studies suggest about restoring vision, memory, liver function, joints, and skin.Why delivering rejuvenation therapies throughout the body is more difficult than treating one localized organ.The difference between oral NMN supplementation and intravenous or subcutaneous NAD.What current research does—and does not—show about growth hormone, testosterone, taurine, metformin, and berberine.Why muscle, exercise, sleep, diet, glucose regulation, and inflammation remain important even if rejuvenation therapies eventually succeed.How Sinclair's laboratory is searching for pills and small molecules that could mimic epigenetic reprogramming without gene therapy.Timestamped Chapters:[04:53] The First Human Trial Begins David discusses ER-100, FDA authorization, and the treatment of open-angle glaucoma and ischemic optic neuropathy.[06:52] What Are the Yamanaka Factors?How reprogramming genes can reset cellular instructions—and why using all four factors can be dangerous.[08:56] Reversing Vision Loss and Memory Problems in AnimalsDavid describes studies involving the eyes, brain, skin, kidneys, liver, and age-related cognitive decline.[10:09] Why Four Factors Can Cause CancerThe difference between restoring youthful function and erasing a cell's identity completely.[10:54] The Three-Gene BreakthroughHow Sinclair's student Yuancheng Lu persisted through years of failure and identified the OSK combination.[12:03] Pulsing the Genes vs. Leaving Them ActivatedEarlier four-factor experiments required intermittent activation, while OSK showed a different safety profile in animal eyes.[13:36] The Doxycycline Safety SwitchHow clinicians may use an antibiotic to activate and deactivate the therapy after it has been delivered.[14:51] Treating the Cause Instead of the SymptomsDavid argues that restoring younger tissue function could allow the body to repair damage associated with age-related disease.[16:02] Why the Trial Starts With the EyeLocalized delivery reduces systemic exposure and makes visual changes easier to observe and measure.[16:50] Can the Therapy Reach the Brain and the Rest of the Body?The challenges of distributing gene-based treatments evenly across organs and through the blood-brain barrier.[18:25] What the Phase 1 Trial Will MeasureSafety, tolerability, visual function, and the possibility of an accelerated development path.[20:36] Expanding Beyond GlaucomaWhy each organ may require a different delivery vehicle—and how the liver could become another early target.[21:38] How Shinya Yamanaka Found the Original Four FactorsThe trial-and-error process that turned adult cells into induced pluripotent stem cells.[22:38] How ER-100 Is DeliveredDavid explains the OSK genes, the AAV delivery system, doxycycline activation, and why manufacturing is expensive.[25:21] When Could the Treatment Become Available?David gives his most optimistic development timeline and discusses parallel programs targeting other organs.[27:31] NMN, NAD, Sirtuins, and the Information Theory of AgingHow declining NAD levels may affect cellular defenses and the regulation of gene expression.[31:34] Oral NMN vs. Injected NADWhy David believes oral supplementation currently has more rigorous evidence than NAD injections.[32:20] Longevity Misinformation OnlineDavid explains why he is restarting his show and warns against confident recommendations unsupported by research.[32:41] Growth Hormone and LifespanWhy growth hormone may improve certain functions but has not been shown to slow aging or extend human life.[34:05] Testosterone, Muscle Mass, and Healthy AgingPotential benefits for maintaining muscle—and why testosterone alone should not be considered a longevity treatment.[36:01] Taurine, Nattokinase, and Changing Your MindWhy David stopped taking taurine regularly and what prompted his interest in nattokinase.[37:30] David's Current Diet and His 86-Year-Old FatherLower meat and cheese consumption, little alcohol, exercise, supplements, and tracking inflammation through biomarkers.[39:33] James's Longevity RoutineLimited processed sugar, intermittent fasting, reduced meat and alcohol, and prioritizing eight hours of sleep.[40:07] Why Sleep Cleans the BrainThe relationship between sleep, waste removal, protein accumulation, cognition, and dementia risk.[40:33] Metformin as a Possible Longevity DrugWhy a medication developed for type 2 diabetes remains central to aging research.[41:41] Berberine and Mitochondrial FunctionWhat clinical studies suggest about glucose regulation and why David sometimes alternates berberine with metformin.[43:10] Modafinil, Adderall, and NootropicsPossible short-term benefits for focus weighed against uncertainty about long-term consequences.[43:43] What Comes After the Eye Trial?Potential applications involving the liver, lungs, kidneys, joints, brain, and other age-related conditions.[45:14] Can Rejuvenation Make Skin Look Younger?David describes unpublished work involving human skin, wound healing, and orally delivered compounds in mice.[46:17] Beyond Gene Therapy: A Rejuvenation PillHow AI and chemical screening may help reproduce the effects of early embryonic reprogramming more cheaply and simply.[47:31] When Could Chemical Reprogramming Reach Humans?David discusses the preclinical safety work and the uncertainty surrounding future human studies.[48:11] The Lifespan Community and FoundationDavid introduces his new show, longevity community, and support for scientific research.Additional Resources:ER-100 Phase 1 Trial — ClinicalTrials.govOfficial registration for the first-in-human study evaluating ER-100 in open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.Life Biosciences: FDA Clearance for ER-100The company's January 2026 announcement that the FDA cleared its Investigational New Drug application.Life Biosciences: First Participant DosedThe June 2026 announcement marking the start of dosing in the Phase 1 trial.“Reprogramming to Recover Youthful Epigenetic Information and Restore Vision” — NatureThe 2020 mouse study reporting that OSK expression restored youthful epigenetic patterns, promoted nerve regeneration, and reversed vision loss.The Sinclair Lab at Harvard Medical SchoolResearch, publications, laboratory members, and information about David's work on the biology of aging.Lifespan: Why We Age—and Why We Don't Have ToDavid Sinclair and Matthew LaPlante's 2019 book about the biology of aging and emerging longevity research.LifespanDavid's longevity show, research magazine, community, and information about the Lifespan Foundation.NMN Human-Trial Review — PubMedA review of the safety evidence and proposed effects of nicotinamide mononucleotide in human clinical studies.NMN and Physical Performance — PubMedA systematic review examining randomized trials of NMN and physical-performance measurements.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of The Sick Podcast, Alex Adams reacts to the signing of defenceman Jordan Spence to a 4-year, $5 million AAV contract extension with the Ottawa Senators! Learn more about your ad choices. Visit megaphone.fm/adchoices

The offseason carousel kept spinning as Washington made a major push by acquiring Jordan Kyrou and Alex Tuch, with Tuch’s new $10.5 million AAV adding another layer to the Capitals’ aggressive retool. Chicago also jumped into the action by landing Bowen Byram and Jordan Greenway, raising the question of whether Connor Bedard is finally getting the support he needs. In Buffalo, Jarmo Kekäläinen takes over with the Sabres still searching for stability in goal, while Ottawa’s addition of William Eklund brings intrigue around where he fits and what Senators fans can expect. Calgary made a bold move of its own by acquiring Simon Nemec and Maxim Tsyplakov from New Jersey, adding more youth and upside to the Flames’ picture. In Edmonton, the Oilers introduced Mike Babcock and DJ Smith, with Ryan Rishaug speaking to Connor McDavid about what the new coaching setup could mean for a team still chasing the final step. Plus, the guys look at whether the Lightning, Penguins, Ducks, Stars, Blue Jackets and Mammoth have more moves coming, and whether Dallas will ultimately move Jason Robertson.See omnystudio.com/listener for privacy information.

Another day, another emergency podcast! This morning, the Oilers announced that they had re-signed Connor Murphy to a five-year extension that carries a $4.1 million AAV. Naturally, we needed to talk about it.

The microphones are live at a noisy, buzzing Boston Pizza Westgate! On this massive Monday edition of The Oil Stream, Dustin Nielson and YouTube Trev are officially on location, and an absolute offseason bomb dropped right before the cameras started rolling. Stan Bowman and the Edmonton Oilers management team have officially locked up shutdown defenseman Connor Murphy to a brand-new five-year contract extension carrying a $4.1 million AAV. The boys waste absolutely zero time diving into the heavy fallout of this massive signature.   On Today's Show: The Connor Murphy Verdict: The trade deadline acquisition is staying in northern Alberta for the long haul! But at 33 years old, is a 5-year term running through his age-38 season an absolute ticking time bomb? The boys break down the $4.1M cap hit, argue over the high-risk vs. high-reward, and slap their official letter grades on the contract. They also dive into the Jason Dickinson deal with the 30-year-old signing on the dotted line yesterday! The Darnell Nurse Domino Effect: Let's read between the lines. If the Oilers are spending $4.1M a year on a veteran defensive specialist like Murphy, what does this mean for the rest of the blue line? The boys break down the cap sheet and ask the million-dollar question: Does this signature mean Stan Bowman is officially pushing all his chips into trading away Darnell Nurse's heavy contract this summer? YouTube Trev's Elite Top 6 Rankings: Shifting gears to league-wide elite firepower, Trev opens up his whiteboard to officially rate the best top-six forward groups across the entire National Hockey League. Who holds the crown, and where do the top-heavy Oilers stack up against the league's best? Dusty's Ultimate UFA Shopping List: With free agency just around the corner on July 1st, Nielson counts down his personal top 5 unrestricted free agent targets he wants to see the Oilers chase to round out the depth chart.   The Oil Stream is live every Monday, Wednesday, and Friday on Edmonton Sports Talk! As always, The Oil Stream is presented by Boston Pizza!

TSN Hockey Insider Darren Dreger dropped by to kick off the show and immediately took the temperature of Oil Country. Dregs breaks down the inner workings of Jason Dickinson's fresh five-year contract extension, unpacking the $4 million AAV, the risk of the term, and what it means for Edmonton's bottom six. From there, we covered all angles of the looming Mike Babcock situation—including an insider's timeline on when an official hiring announcement could drop. Plus, with the Oilers facing a massive salary cap crunch, Dregs gives us the latest on the Darnell Nurse trade rumors and management's blueprint going forward. Finally, we switched gears to react to the absolute blockbuster trade that shook the hockey world yesterday, as Brady Tkachuk heads to South Florida to reunite with his brother, leaving the Ottawa Senators searching for a brand new identity.   It was then time for the Play Alberta Early Bird Bet of the day.   After the break, we got into MMMMMM That's Good presented by The Italian Centre Shop! What's good today is how unreal Justin Rankin's season has been thus far.   We finished hour two with Offseason, What Offseason presented by GCL Diesel. YouTube Trev's trade of the day continues… and the nasties absolutely hated this one.

Many disease‑causing genes are too large to be packaged into standard AAV gene therapy vectors, leaving a long list of otherwise gene-therapy-ready conditions without viable treatments. SpliceBio is leveraging a protein splicing platform based on engineered split inteins to overcome the cargo limitations of AAV gene therapy vectors, enabling delivery of large genes to potentially treat a broad range of monogenic conditions. The company's lead program is a dual AAV gene replacement therapy to treat Stargardt disease, a rare inherited condition that causes progressive vision loss. Miquel Vila-Perello, CEO of SpliceBio, discusses the company's platform technology that enable to the delivery of large genes in AAV vectors, its work to date in Stargardt disease, and preclinical data across more than 20 large-gene targets supporting its platforms use in ophthalmology and CNS indications.

Judd and AJ react to the news of Michael McCarron re-signing with the Minnesota Wild on a 6-year, $3.3 million AAV contract. How do you feel about the deal? Does this put any other members of the roster in jeopardy? Plus more!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Judd and AJ react to the news of Michael McCarron re-signing with the Minnesota Wild on a 6-year, $3.3 million AAV contract. How do you feel about the deal? Does this put any other members of the roster in jeopardy? Plus more!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

More trade targets...this Detroit Red Wings podcast breaks down Red Wings trade possibilities other than Petterson - from Matt Barzal to Mason McTavish and beyond. News and analysis digs into Steve Yzerman's middle-tier trade targets, Stanley Cup Final Game 1, NHL All-Star changes, and two prospect profiles ahead of the draft. (00:00) - Intro (04:05) - Matt Barzal Trade Talk Barzal's market is reportedly being explored - what the Islanders would want, why his speed and term make sense for Detroit, and whether the acquisition cost is even close to reasonable. (18:55) - Mason McTavish and Shane Wright A reclamation project breakdown on McTavish coming off a missed camp and contract dispute, plus whether Shane Wright's pedigree is inflating his price in Seattle. Kent Johnson sneaks into the conversation too. (34:05) - Samoskevich and Vincent Trocheck Samoskevich as an RFA offer sheet wildcard out of Florida and why Trocheck's age makes the Rangers asking price tough to stomach, even with the cap-friendly AAV. (41:40) - Stanley Cup Final Game 1 A nine-goal shootout in Carolina with Tomas Hertl burying the winner for Vegas. Mitch Marner enters the Conn Smythe conversation and Nikolaj Ehlers makes his case too. (46:30) - All-Star Game Changes Country vs. country 3-on-3 format returns, the skills competition gets a 25-and-under cap with a $1M prize, and how the league could actually make it watchable. (51:35) - Prospect Profile: Caleb Malhotra Manny's kid headed to Vancouver? The pro-style center, the Brantford context, and whether his floor justifies a top-five pick. (59:20) - Prospect Profile: Alexander Bilecki The Memorial Cup champion Kitchener defenseman as a possible fit at pick 47, with an Albert Johansson comparison baked in. (1:06:10) - Overtime Patron questions on Mavrik Bourque as a 2C solution, the early vs. late birthday draft factor, Jaccob Slavin envy, and more. --- This episode is brought to you by Hims. Visit hims.com/wingedwheel for your personalized hair loss treatment options. Support the show: Patreon.com/WingedWheelPodcast Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more!

It's time - this Detroit Red Wings podcast breaks down the 2026 NHL Draft strategy for Steve Yzerman with no first-round pick in hand. News and analysis covers Yzerman's free agency options, prospect profiles, Stanley Cup playoff updates, and a coaching shakeup in Toronto. (00:00) - Intro Free agency is looking THIN. (04:25) - 2026 Draft Strategy With no first-round pick after the Justin Faulk trade, what should Kris Draper and the Red Wings do? The case for swinging for the fences and avoiding the safer Brady Cleveland/Andrew Gibson archetype that's burned them in the past, and how they can get a Stankoven or Hutson of their own. (13:25) - Trading Up in the Draft Is moving up worth the cost? Why Sebastian Cossa probably isn't getting it done on his own, and why the 33-38 range could be the sweet spot for catching fallers. (40:35) - Prospect Profile: Gavin McKenna Sick puck skills, Kucherov-level vision, and questions about his off-puck effort. Why he's still the favorite to go first overall over Stenberg. (49:45) - Prospect Profile: Victor Plante Max Plante's brother and what he could bring as a potential second-round target. (56:30) - Stanley Cup Playoff Updates Charlie McAvoy's suspension, the diving problem, and Carolina sitting back watching Montreal and Buffalo beat each other up. (1:02:45) - NHL news: Berube Fired by Toronto; Cassidy in Demand Why the move had to happen and what kind of coach the Leafs need next. Vegas blocking interview requests and Edmonton's never-ending dysfunction. (1:11:05) - Charlie Coyle Contract Six years, $6 million AAV, full no-move through age 38 - what does this mean for this year's July 1st market?> (1:19:55) - Overtime Questions Your questions on Kyrou, Brady Tkachuk rumors, Mackie Samoskevich, and more. --- This episode is brought to you by Hims. Visit hims.com/wingedwheel for your personalized hair loss treatment options. Support the show: Patreon.com/WingedWheelPodcast Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more!

Marty Makary's hold on the top job at FDA is slipping, with White House leaks about President Donald Trump's displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin discusses the pressures on Makary, how long he will hold onto his post, and the leading candidates to succeed him.BioCentury's analysts then discuss solutions to AAV's redosing problem, which could reignite industry interest in a modality that has fallen out of favor, and other topics in the spotlight at this week's American Society of Gene and Cell Therapy annual meeting. The analysts also discuss opportunities to attend and present academic posters at the third BioCentury Grand Rounds U.S. conference June 3-5 in Seattle. This episode of the BioCentury This Week podcast has been brought to you by Jeito Capital.View full story: https://www.biocentury.com/article/659426#FDA #GeneTherapy #AAV #CellTherapy #Biopharma00:01 - Sponsor Message: Jeito Capital01:43 - Bio€quity Europe Prague Highlights04:54 - Makary on Thin Ice14:37 - Grand Rounds Poster Pitch16:40 - AAVs at ASGCTTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Another March Sadness episode. This Detroit Red Wings podcast covers the Red Wings vs Senators crushing loss in what should have been their most winnable big game of the season. Hockeytown news and analysis breaks down where the playoff race stands, Larkin's return, and Yzerman extending JBD. (00:55) - Intro (03:30) - Ottawa Loss Breakdown Red Wings fall to injury-depleted Senators on back-to-back despite Ottawa missing five defensemen including Jake Sanderson. Discussion on the Patrick Kane offside that negated an Alex DeBrincat goal, plus how Dylan Larkin's return, Yakemchuk's guaranteed goal, and DeBrincat and Zub's fight all ended in disappointment for Todd McLellan's squad. (27:45) - Playoff Race Math Breaking down where Detroit sits after the regulation loss and which teams they need to leapfrog with limited games remaining - can Steve Yzerman's roster do it? How much can Moritz Seider and Simon Edvinsson support from the back end for a stagnant offense? (38:20) - Jacob Bernard-Docker Extension Steve Yzerman extends JBD to a 2 year, $1.6 million AAV extension - what this means for the blue line depth, Axel Sandin-Pellikka, and future moves. (46:00) - Axel Sandin Pellikka Sent Down ASP returns to Grand Rapids Griffins before the Ottawa game - how is his path affected? (53:40) - NHL Suspension Debate Around the league discipline decisions and how stars like Connor McDavid may affect future changes with George Parros and Gary Bettman. (1:05:00) - Overtime Q&A Your questions on the March sadness in Hockeytown and whether it's truly over for the Red Wings' playoff hopes. --- Jessi Pierce Family Fundraiser: https://www.gofundme.com/f/support-mike-hinrichs-after-losing-jessi-pierce-children This episode is brought to you by Hims. Visit hims.com/wingedwheel for your personalized hair loss treatment options. Support the show: Patreon.com/WingedWheelPodcast Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more!

Ian Reid and Erik Kuhre discuss the Sharks signing forward Kiefer Sherwood to a 5 year, $5.75 million AAV deal from a quiet Stanley's Sports Bar at Sharks Ice. Teal Town USA - A San Jose Sharks' post-game podcast, for the fans, by the fans! Subscribe to catch us after every Sharks game and our weekly wrap-up show, The Pucknologists!
 Check us out on YouTube and remember to Like, Subscribe, and hit that Notification bell to be alerted every time we go live!


Ben Verlander previews the World Baseball Classic now that the rosters have been set. He also talks about the best lineup, rotation & team in the WBC. The Detroit Tigers surprised the baseball world by giving Framber Valdez the highest AAV for the left-handed pitcher & Tarik Skubal also won his record arbitration deal. That and so much more on Flippin' Bats. CHAPTERS:00:00 INTRO01:30 TIGERS SIGN FRAMBER VALDEZ07:00 TARIK SKUBAL'S RECORD DEAL18:00 WORLD BASEBALL CLASSIC PREVIEW19:30 POOL A23:10 POOL B29:00 POOL C31:50 POOL D35:50 BEST LINEUP38:30 BEST ROTATION39:50 BEST TEAM42:50 TOP 10 TEAMS46:30 OUTRO Learn more about your ad choices. Visit megaphone.fm/adchoices

Benny & the Wings! This Detroit Red Wings podcast breaks down Ben Chiarot's new three-year, $3.85 million AAV extension & whether it was a good signing by Yzerman. Our Detroit Red Wings news and analysis covers the contract details, Simon Edvinsson's injury update, and the playoff race heating up in the Atlantic Division. (00:00) - Intro & Red Wings Gift Surprise Special delivery from the Detroit Red Wings organization sets up an exciting episode finale. (04:15) - Ben Chiarot Extension Breakdown We debate the merits & drawbacks of the new contract as Chiarot takes a pay cut to stay in Hockeytown for 3 more years, avoiding 35-plus contract complications with straight salary structure. We discuss how Chiarot provides veteran leadership & snarl as Detroit builds depth behind Moritz Seider and Simon Edvinsson on the blue line. (23:30) - Simon Edvinsson Injury Update Latest news on Edvinsson's status and what it means for Todd McLellan's defensive pairings. (27:50) - Kings Game Recap & Analysis Red Wings' anemic performance against Los Angeles, including DeBrincat's sole Detroit goal, Patrick Kane tying Mike Modano's record, and key takeaways from the matchup. (36:50) - Atlantic Division Playoff Race Standings update as Detroit battles for positioning in the competitive Atlantic Division landscape, as the Buffalo Sabres are still surging. (44:40) - NHL Trade News & Market Analysis League-wide moves and how they impact Steve Yzerman's approach to the trade deadline, and whether players like Schneider or Panarin are worth it from the Rangers. Also, more not-so-joking jokes about acquiring Robert Thomas and Justin Faulk. (54:50) - Overtime Q&A Listener questions on the Chiarot deal, defensive depth, and Red Wings roster construction moving forward. (1:06:15) - Red Wings Surprise Gift Reveal --- WWP Night at the LCA Night (March 21st) tickets at wingedwheelpodcast.com/redwings This episode is brought to you by Hims. Visit hims.com/wingedwheel for your personalized hair loss treatment options. Support the show: Patreon.com/WingedWheelPodcast Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more!

We're speculating about whether short-term, high AAV contracts are becoming the new norm in MLB. -Elly Turns Down Record Contract -Mookie Will Retire After 2032 -Verlander's Next Team -HOF Reveal Tuesday -Jayhay's Bichette Takes -Sal Frelick Tomorrow! Use promo code “Jared” to get up to $1000 in bonus credits AND a special pick on Underdog! PLAY HERE: https://play.underdogfantasy.com/pc-d2PyPbHAPu 0:00 - Trying New Food 10:10 - NFL Playoffs 14:35 - Reds / Elly Offer 22:00 - New CBA 25:15 - Guess That Player 37:02 - Betts Retirement 40:00 - Tide Shift 47:00 - Verlander Interest 1:00:35 - HOF Reveal 1:12:37 - Jayhay Nuggs 1:13:30 - Final Thoughts Learn more about your ad choices. Visit megaphone.fm/adchoices

Segment 1 – News and Notes1.    The Dodgers made a splash by signing Kyle Tucker to the largest AAV in history – 4 years and $240 million with opt-outs after 2027 and 2028.8.a.    A lot of people are upset about the dominance of the Dodgers.  “They are ruining baseball!”  What say you?b.    Were you surprised that Tucker signed a shorter deal but for more money?c.    The odd thing is that he's not even the best player on the team, maybe not even the top 3 players on the team.d.    I don't see any playing time loss for anyone with the exception of a potential delay in the arrival of Josue DePaula or Zyhir Hope.  Do you see anything?2.    The Mets were spurned by Tucker and pivoted to Bo Bichette, signing him to a massive three-year, $126 million deal with a unique opt-out clause.  He can opt out after each year, and if he does, the Mets have to pay him a $5 million bonus. a.    $42 million a year for Bichette?  Thoughts on the signing?b.    He'll likely play third base.  Who sits out of Baty or Vientos?c.    Also, I think Jett Williams needs to learn the outfield, plus, with the Mets not getting Tucker, Benge is still safe – for now.  Thoughts?3.    A small but interesting, three-way trade was pulled off by the Angles, Rays and Reds.  The Rays sent Josh Lowe to the Angels and Gavin Lux to the Rays, with the Reds acting as the intermediary. The Angels shipped RHP Chris Clark to Tampa Bay and LHP Brock Burke to Cincinnati.a.    Who's value goes up more?  Lowe, Lux, or neither?b.    Does this open a chance for Jacob Melton in Tampa?c.    Will Lux ever be more than an afterthought?Segment 2 – Third Base Rankings for the 2026 Season1.    How are you approaching this position for your upcoming drafts?2.    We will break down the top 15 to 20 in detail.  Then, go through 20 to 30 in less detail.  We will end by jumping around the remaining ranked players.3.    Which player not in the Top 10 has a chance to emerge there next season?4.    Which Top 10 player will not be there next season?5.    Give me a couple of sleepers6.    Give me one, maybe two guys you are just going to avoid drafting?

Evan unloads a full conspiracy theory: Rob Manfred is not mad about the Dodgers dominating baseball, he's thrilled. The idea is simple and terrifying. Let the Dodgers keep stacking stars, let fans scream “baseball is broken,” and then use that outrage to win the PR war for a salary cap the players will hate. Tiki buys it immediately, even as they admit it still might never work. From there, the focus snaps back to the Mets problem that keeps getting louder: they can “try” for Tucker, but where's the backup plan? A caller compares Cashman's quick Soto pivot to the Mets dragging their feet, and the guys dig into the bigger issue: Stearns will spend huge AAV, but refuses to go long term, which kills half the market. Then it turns into pure show chaos: Free Agent Bingo standings, Knicks misery, and Mets fans roasting the offseason, including a fake “Mets fan” troll call and the return of the “chomping at the bit” debate right before Evan teases a pivot plan that does not include Cody Bellinger.

The show comes to a screeching halt with legitimate breaking news as the Mets land Bo Bichette on a three-year, $126 million deal, and Evan immediately reminds everyone he called the pivot before it happened. Evan and Tiki react in real time to the signing, the massive AAV, the opt-out structure, and what this move says about how David Stearns is operating in the market. They break down where Bichette fits defensively, why third base appears to be the early plan, and how much offensive ground this actually recovers after losing Pete Alonso and Kyle Tucker. The guys debate the risk of one-year and two-year opt outs, the surprising draft pick cost, and whether this is a necessary concession in today's marketplace. Plus, what this move means for Philadelphia after reportedly agreeing to a long-term deal, how Toronto now pivots, why Cody Bellinger still does not make sense for the Mets, and whether this finally changes the tone of a chaotic Mets offseason. Live calls, instant reactions, and a full breakdown of how the roster and expectations shift after the biggest move yet.

With Kyle Tucker off the board, the Mets are staring into the void and Evan lays out why Cody Bellinger is not a realistic “panic buy,” even with rumors of the Yankees sitting around five years and $160M. If the Mets wouldn't go long for Tucker or Alonso, why would they suddenly cave to Scott Boras? Then the debate turns into the uncomfortable part: what's the actual pivot? Evan pitches a wild, short-term, mega-AAV idea for Bo Bichette that's basically a Tucker-style offer to blow him away, get an opt-out, and take another swing at free agency before 30. The problem: where does he play, and how much run prevention are you willing to sacrifice to get a real bat? Tiki pushes back on the defensive domino effect, the “versatility” trap, and the weekly second-guessing Mets fans would live through. The guys kick around the alternatives (including a one-year Eugenio Suárez power play), plus why pitching still has to be the priority no matter what. And of course, the segment ends with the same challenge: if you hate the plan, tell us a better one.

The Mets offseason is at a tipping point, and Kyle Tucker is the one move that could change the entire mood. Evan and Tiki debate why Tucker would “save” the winter, why the Mets' only real edge is money, and how David Stearns' short-term, high-AAV philosophy is shaping everything after losing Pete Alonso. Then it turns into a wild New York sports morning: John Harbaugh meets with the Giants, fans call in on Tucker vs pitching help (Suarez, Valdez, Giolito), and the guys hit the Yankees' under-the-radar Ryan Weathers trade before circling back to the big question: who's the Mets ace right now? Chapters 00:00 Kyle Tucker “saves” the Mets offseason 03:20 Mets vs Dodgers vs Blue Jays and what actually matters 06:25 Trusting Stearns, roster “maybes,” and the first base frustration 14:00 Giants news: John Harbaugh meeting and the Tisch plane buzz 18:30 Calls: Tucker vs Suarez/Valdez, plus the rotation anxiety 35:15 Yankees add Ryan Weathers, then Giolito and the Mets “ace” debate

Evan and Tiki open the phones and Mets fans go straight to the big question: if you can only make one marquee move, is it Kyle Tucker or a top arm like Ranger Suárez or Framber Valdez? Evan argues Tucker's 162-game impact is bigger than any starter's, even while admitting the rotation still screams for certainty. The conversation rolls into David Stearns' short term, high AAV strategy, whether “connections” matter at all in free agency, and why the Dodgers are always lurking if money is close. Plus: the Pete Alonso fallout won't go away, the “is $50M worth it?” camps battle, the Yankees finally make an under the radar move with Ryan Weathers, and a caller throws Lucas Giolito into the mix as the show debates what actually qualifies as a Mets ace right now.

The Mets are making a real push for Kyle Tucker, with reports of a massive short term, high AAV offer that fits David Stearns and Steve Cohen's recent roster philosophy. The crew debates whether the Mets can actually beat out the Dodgers or Blue Jays, and why Tucker might prefer a short deal to reenter a thin future free agent market.

While Wild Card Weekend dominated the headlines, a major MLB bomb dropped in the background. The New York Yankees are now operating under the assumption that Cody Bellinger could sign elsewhere as contract talks stall over years, not dollars. Evan, Tiki, and Shaun break down the reported standoff with Scott Boras, why the Yankees are refusing to negotiate against themselves, and why this situation feels eerily similar to what the New York Mets dealt with last year. The conversation pivots to potential fallback options, including interest around Kyle Tucker, the realities of short term high AAV deals, and why teams like the Los Angeles Dodgers and Toronto Blue Jays loom large in the background. Plus, a deeper debate on free agency leverage, market reality, and why Yankee fans may want to stay calm as this staring contest plays out.